



February 14, 2023

The Manager- Listing
BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai - 400001

The Manager- Listing

National Stock Exchange of India Limited

Exchange plaza, 5th Floor, Plot No. C/1, G Block
Bandra –Kurla Complex, Bandra (E),
Mumbai - 400051

Dear Sir,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

This is to inform that AstraZeneca Pharma India Limited has received a no objection for an additional/expanded indication from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India, for Durvalumab (Imfinzi™) 120 mg/ 2.4 ml and 500 mg/ 10 ml solution for infusion.

Through this approval, “Durvalumab (Imfinzi™) in combination with chemotherapy is indicated for the treatment of patients with locally advanced or metastatic biliary tract cancer (BTC)”.

The receipt of this permission paves way for the launch of Durvalumab (Imfinzi™) solution of 120 mg/ 2.4 ml and 500 mg/ 10 ml in India for the specified additional/expanded indication, subject to the receipt of related statutory approvals, if any.

We request you to take the above intimation on record.

Thanking you
Yours faithfully

For **AstraZeneca Pharma India Limited**

Manasa. R
Company Secretary

CORPORATE & REGD. OFFICE
AstraZeneca Pharma India Ltd.
P. B. No. 4525, Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bangalore - 560 045, INDIA

TEL : +91 80 6774 8000

FAX : +91 80 6774 8857

CIN : L24231KA1979PLC003563

WEB : www.astrazeneca.com/india

FACTORY

12th Mile on Bellary Road
Venkatala, Kattigenahalli Village
Yelahanka
Bangalore - 560 063
INDIA

TEL : +91 80 6774 9000

FAX : +91 80 2846 2208
+91 80 6774 9628